Reilly Financial Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Reilly Financial Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$5K	Hold	2,000	–	–	﹤0.01%	837
2021 Q3	$5K	Hold	2,000	–	–	﹤0.01%	748
2021 Q2	$6K	Hold	2,000	–	–	﹤0.01%	769
2021 Q1	$5K	Hold	2,000	–	–	﹤0.01%	792
2020 Q4	$4K	Hold	2,000	–	–	﹤0.01%	730
2020 Q3	$2K	Hold	2,000	–	–	﹤0.01%	754
2020 Q2	$2K	Hold	2,000	–	–	﹤0.01%	817
2020 Q1	$2K	Hold	2,000	–	–	﹤0.01%	794
2019 Q4	$2K	Hold	2,000	–	–	﹤0.01%	811
2019 Q3	$2K	Hold	2,000	–	–	﹤0.01%	825
2019 Q2	$2K	Hold	2,000	–	–	﹤0.01%	868
2019 Q1	$3K	Hold	2,000	–	–	﹤0.01%	861
2018 Q4	$2K	Sell	2,000 -286	-13%	-$438	﹤0.01%	858
2018 Q3	$5K	Hold	2,286	–	–	﹤0.01%	828
2018 Q2	$4K	Hold	2,286	–	–	﹤0.01%	847
2018 Q1	$5K	Hold	2,286	–	–	﹤0.01%	778
2017 Q4	$4K	Hold	2,286	–	–	﹤0.01%	811
2017 Q3	$6K	Buy	+2,286	New	+$5.67K	﹤0.01%	723

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Reilly Financial Advisors's LCTX Position: Q4 2021 in Review

Reilly Financial Advisors held its Lineage Cell Therapeutics (LCTX) position steady in Q4 2021 at 2,000 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #837.

Reilly Financial Advisors first reported a position in LCTX in Q3 2017 and has held it in 18 quarters since. The position peaked at $6K in Q2 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

Reilly Financial Advisors held 2,000 shares of Lineage Cell Therapeutics worth $5K as of Q4 2021.
Reilly Financial Advisors left its Lineage Cell Therapeutics share count unchanged in Q4 2021.
Lineage Cell Therapeutics made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #837 holding.
Reilly Financial Advisors first reported a position in Lineage Cell Therapeutics in Q3 2017 and has held it in 18 quarters since.
Reilly Financial Advisors's Lineage Cell Therapeutics position peaked at $6K in Q2 2021.
124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.